FTO and acute myeloid leukemia: Su et al., 2020 [81] have demonstrated the clinical significance of two synthetic small-molecule inhibitor of FTO, designed on the basis structural guided tool, (CS1 and CS2) in controlling AML, especially leukaemia stem cell (LSC) progression.